Home > Healthcare > Pharmaceuticals > Finished Drug Form > Muscle Relaxant Drugs Market
Muscle Relaxant Drugs Market Share
- Report ID: GMI6559
- Published Date: Aug 2023
- Report Format: PDF
Muscle relaxant drugs Market Share
The prominent players in the muscle relaxant drugs market are
- Amneal Pharmaceuticals LLC
- Ipsen Biopharmaceuticals, Inc
- Merz Pharmaceuticals, LLC
- Mylan (Viatris)
- Sanofi
- Pfizer Inc
- Novartis AG
- eva Pharmaceuticals Industries Ltd, Inc
- Vertical Pharmaceuticals
- Sun Pharmaceutical Industries Ltd
- SteriMax Inc
- Par Pharmaceutical
- Abbott Laboratories
- F. Hoffmann-La Roche AG
These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.
Frequently Asked Questions (FAQ) :
The global muscle relaxant drugs industry size was USD 4.1 billion in 2022 and will reach USD 9.4 billion by 2032 with a CAGR of 6.4% from 2023 to 2032.
The muscle spasm & pain relief segment is expected to reach USD 4 billion by end of 2032 owing to the widespread need for efficient solutions to manage muscle-related discomfort.
North America muscle relaxant drugs market held 37.6% revenue share in 2022 and is anticipated to show considerable growth during 2023-2032 attributed to the growing aging population, sedentary lifestyles, and occupational stress.
Amneal Pharmaceuticals LLC, Ipsen Biopharmaceuticals, Inc, Merz Pharmaceuticals, LLC, Mylan (Viatris), Sanofi, Pfizer Inc, Novartis AG, Teva Pharmaceuticals Industries Ltd, Vertical Pharmaceuticals, Sun Pharmaceutical Industries Ltd, SteriMax Inc, Par Pharmaceutical, Abbott Laboratories and F. Hoffmann-La Roche AG.
Muscle Relaxant Drugs Market Scope
×
Get a free sample of
Muscle Relaxant Drugs Market
Inquiry Before Buying
Get special pricing options on this report
Request Sectional Data
Over 70% of our clients customize reports to fit their needs. Please tell us how you would like to customize yours
below